Ask what your plan pays for, by name.

Translate the plan’s words

Formulary

The plan uses this word for its covered-medicine list.

Prior authorization

This means the plan asks for approval before it will pay for the proposed care.

Self-pay

Ask whether the quoted amount assumes you pay without using insurance.

• Will my plan pay for the named medicine for the purpose written on my prescription?
• Who sends any approval request, and what happens if it is declined?
• What amount would I owe for the visit, product and lab work?
• Can I have the answer and a call reference in writing?

If the offer is for weight care

Your body’s GLP-1 hormone carries signals affecting hunger and blood sugar. Two medicines that copy its action are semaglutide and tirzepatide.

FDA is short for the Food and Drug Administration, the U.S. agency that reviews medicines.

The FDA had approved semaglutide products Ozempic and Wegovy by September 26, 2026.

Tirzepatide products with FDA approval on September 26, 2026 were named Mounjaro and Zepbound.

Part D is Medicare’s prescription-medicine benefit. Its basic benefit excludes medicines used for weight loss under the rules dated September 26, 2026.

A different accepted use, such as diabetes, can open a route to Part D coverage, but the plan’s own drug list and approval steps still matter.

A separate, temporary route

Medicare GLP-1 Bridge is a temporary payment programme for certain weight-loss medicines. Its September 26, 2026 terms set the patient’s share, or copay, at $50 per eligible monthly supply.

July 1, 2026 was the start; the programme is due to run until December 31, 2027.

In 2026, a central service handles Bridge approval requests and payments to pharmacies, rather than your usual Part D plan’s payment system.

Each $50 Bridge payment leaves you no closer to reaching Part D’s yearly limit on your own spending. These payments are extra spending outside that limit.

Bridge eligibility depends on age, health, plan and product conditions; a prescription and advance approval are also required.

Someone with type 2 diabetes cannot enter the Bridge; that use of treatment goes through normal Part D consideration.

Use the product’s name when asking the prescriber and plan which payment route applies. This programme is not a general peptide-care benefit.

Reading beside this chapter

• Medicare’s Bridge overview

  Read the programme terms before treating its copay as your expected bill.

• The Bridge’s eligibility and product details

  This is the detailed route for checking whether the proposed medicine and your circumstances fit.